Stenosis or occlusion of the central veins and/or vena cava can cause painful and debilitating symptoms for affected patients. Superior vena cava syndrome (SVCS) can develop acutely or progressively from external compression or intrinsic obstruction. The clinical signs and symptoms result from venous hypertension and reduced blood flow in the superior vena cava (SVC) or central veins emptying into the SVC. Depending on the anatomic location of the narrowing, clinical symptoms, and presentation will vary. Clinical signs include cyanosis, plethora, distention of subcutaneous veins, and edema of the upper extremities, head and neck. Edema may compromise laryngeal or pharyngeal function, causing dyspnea, stridor, cough, hoarseness, and dysphagia. 1 Although there may be symptom overlap with congestive heart failure, a physical examination will usually delineate between the two diagnoses.
The etiology of SVCS varies and can be broadly grouped into benign and malignant causes, with most strictures of the caval system and venous tributaries being malignant. 2, 3 Nonsmall-cell lung cancer (NSCLC) is the most common malignant cause of SVCS, followed by small-cell lung cancer (SCLC) and non-Hodgkin lymphoma. 4 The most common causes of benign venous stenosis involve the presence of an indwelling intravascular device (i.e., catheters, pacemaker/defibrillators, ports). Arteriovenous fistula related obstruction, mediastinal fibrosis, and prior thoracic external bean radiation therapy are additional benign causes.
Treatment of central venous occlusions depends on the etiology and clinical presentation. The ultimate goal of therapy is to correct the obstruction and alleviate the symptoms. Conservative measures depend on the etiology and include limb elevation, steroids, anticoagulation, chemotherapy and/or radiation therapy, and diuretics. 5 Interventional therapies include surgical bypass and/or endovascular stent placement. Guide wire recanalization and endovascular stenting is a minimally invasive procedure that can be performed on an outpatient basis with standard equipment available in an angiography suite. The procedure below describes the authors approach to treating chronic central venous occlusive disease.
Preprocedural Evaluation
Initial evaluation of the patient begins with a focused history and physical examination, and review of any available imaging. Cross-sectional imaging with either contrast-enhanced computed tomography (CT) or magnetic resonance (MR) is extremely helpful to delineate the anatomy of the lesion and assist in procedural planning. Both CT and MR can be used to diagnose any underlying pathology, including tumor size and localization. 1 Thin section, contrast-enhanced CT is especially useful to determine the amount of venous stenosis/occlusion, identify prominent collateral vessels, and identify anatomic landmarks to avoid during recanalization. Routine laboratory tests including blood counts and serum chemistries are obtained on the day of the procedure. Optimal laboratory values include a serum creatinine < 1.5 mg/dL with an estimated glomerular filtration rate > 60, and a platelet count of > 50,000/dL. In the outpatient setting, the authors recommend holding or reversing anticoagulation for this procedure so the interventionalist can administer intraprocedural unfractionated heparin and monitor anticoagulation levels during the procedure.
Procedure
When procedures are expected to be prolonged or challenging, the authors typically perform them with general anesthesia for patient comfort, however, moderate sedation using intravenous fentanyl and midazolam can also be used. The patient is positioned supine on the fluoroscopic table and depending on preference for vascular access, the upper extremity, and neck ipsilateral to the venous occlusion is prepped using the standard sterile technique. The right groin is also prepped as access into the right common femoral vein (CFV) is routinely gained during the procedure to assist in recanalization. Perioperative intravenous antibiotics are administered (1 g cefazolin), and systemic anticoagulation with unfractionated heparin is routine.
Depending on the location of the occlusion, under direct ultrasound guidance venous access into the ipsilateral upper extremity or neck is achieved with a 21 gauge micropuncture set and a 30-cm 6F vascular sheath (Cook Inc., Bloomington, IN) is placed. The long sheath not only provides an adequate sized working conduit, but also provides stability and stiffness for the system. Venography of the involved vessels adjacent to the lesion is performed to delineate the anatomy of the occlusion for procedural planning. Simultaneous venography performed through sheaths or catheters on each side of the occlusion is also useful to evaluate the length of the occlusion. Through the 6F vascular sheath and over an angled Glidewire (Terumo Medical Corp., Somerset, NJ), an angled 5F Kumpe catheter (Cook Inc.) is advanced to the stump of the venous occlusion. Under fluoroscopic guidance, the Glidewire is advanced out the tip of the catheter toward the occlusion, using graded force. Gently probing with the Glidewire may be adequate to cross severe stenoses or acute occlusions. If the wire fails to traverse the occlusion, incrementally greater force is used with the wire. Advancing the angled catheter and sheath against the occlusion will give the Glidewire more stiffness and will direct the tip of the wire directly into the lesion. If the tip of the wire will not advance into the lesion after these techniques the lesion will be probed with the stiffer back end of the Glidewire. The advantage is that as the wire exits the catheter tip, it creates a very sharp point; however, it is very easy to place the wire in the extravascular space with this technique and caution should be used. The authors will frequently use a combination of the tip and the "back end" of the Glidewire by alternating between the two for longer recanalizations; this is performed by pushing into the occlusion with the "back end" of the Glidewire and, as incremental distance through the occlusion is gained, advance the catheter is further advanced into the occlusion, and the wire is again reversed to probe with the tip of the Glidewire. A loop snare (eV3 Endovascular Inc., Plymouth, MN) or pigtail catheter can be placed at the distal (downstream) margin of the occlusion via the CFV vascular access to provide a visible target for wire placement. Frequent rotation of the fluoroscopic unit is required to ensure that recanalization is progressing in the correct direction.
Once the lesion is crossed, the 5F catheter is advanced past the occlusion over the wire, and intraluminal position is verified with aspiration of blood. Once the blood is aspirated, a gentle venogram is performed to confirm reentry into the vessel lumen. As it is not uncommon for the catheter to not follow the wire through parts of the tract, the use of an exchange length wire is critical to allow snaring the wire from the CFV access and pulling the wire for a through-andthrough access; through-and-through access allows a stiff rail that almost always allows for advancing a catheter through an occlusion. If a conventional catheter still does not pass, a tapered crossing catheter such as a Quick Cross (Spectranetics, Colorado Springs, CO) may be helpful. When the catheter itself is externalized at the groin access site, an exchange length stiff wire (260 cm Amplatz; Cook Inc.) can be positioned across the lesion. Venoplasty before the stent placement is typically performed; the authors usually underdilate the stenosis with a 4-to 5-mm balloon; this is performed to allow the passage of a stent. Aggressive overdilation is avoided initially, particularly when recanalizing the SVC to avoid a potentially fatal rupture into the pericardial space with resultant pericardial tamponade. When making measurements for stent placement, a 5F marker pigtail catheter (Cook Inc.) is placed over the wire, and a simultaneous venogram is performed through the sheaths above and below the occlusion. Once measured, a selfexpanding nitinol stent is deployed across the lesion, and venoplasty is performed with increasing sizes of balloons and intermittent venography to evaluate for residual stenosis/thrombosis, reduction of collateral blood flow, and to assess for complications (►Fig. 1). If contrast extravasation is detected into the pericardial space, anticoagulation is reversed, balloon tamponade across the prior obstruction is performed, and ultrasound is made available for potential emergent pericardiocentesis.
In the authors practice, initial attempts at chronic venous recanalizations are made with a catheter and hydrophilic wire, as many occlusions can be traversed with this method. If the lesion is recalcitrant to hydrophilic wire traversal, an attempt at sharp recanalization (►Fig. 2) using a 15-to 65-cm 21-gague Chiba tipped needle (Cook Inc.) is made. When positioning the needle toward the occlusion, care should be taken not to pierce the sheath with the Chiba tip. The needle is placed in coaxial fashion through the vascular dilator included with the sheath, and the needle tip is exposed only once the dilator reaches the lesion. Short, purposeful, and quick passes with the needle are made. A marker pigtail catheter or snare placed at the opposite side of the occlusion is mandatory when attempting sharp recanalization, and frequent image intensifier rotation will help to evaluate the needle tip position relative to the target. Aspiration is performed while withdrawing the needle and, if blood is aspirated, contrast is gently injected to evaluate for intravascular positioning. A slight bend or graduated curve to the distal needle can be formed for additional direction control. If sharp recanalization is unsuccessful or thought to be unsafe for the patient, a 250cm 0.035-in. PowerWire Radiofrequency (RF) Guidewire (Baylis Medical, Montreal, Québec, Canada) can be used for more challenging or long segment recanalizations (►Fig. 3). Through the indwelling venous guide sheath, the RF wire is advanced through the angled catheter toward a target snare in short (3-5 mm) increments. A 25 Watt power is applied for 2 second pulses with a dedicated RF generator, under fluoroscopic guidance. Once the wire is advanced, through the occlusion the tip of the 250 cm RF wire can be snared or the 5F catheter can be advanced over the wire. Once "through-and-through" access is achieved, balloon venoplasty and stent placement is similar to what is previously described. 
Postprocedural Evaluation
Postprocedurally, the patients are transferred to the postanesthesia care unit for cardiovascular monitoring. It is typical for patients to be on bed rest precautions for 2 to 4 hours due to the CFV puncture and the systemic intraprocedural anticoagulation. If the CFV was not accessed, the bed rest precaution time is reduced. If flow was restored after the procedure, systemic anticoagulation is not typically necessary unless there is residual thrombus. Low-dose aspirin (81 mg) is given for several months to allow the coverage of the stent with neoendothelium. In the authors practice, patients are seen back in a clinic setting 1 to 2 weeks after the procedure.
Summary
Chronic central venous occlusion can be a debilitating condition for patients. Malignancy, such as NSCLC, is the most common etiology although indwelling intravascular devices, prior thoracic radiation therapy, and fibrosing mediastinitis can cause chronic central venous occlusions as well. Treat-ment goals are focused on symptomatic relief and, if the etiology is malignancy, treatment is often palliative. Percutaneous recanalization and endovascular stenting of chronic occlusions is a minimally invasive technique that can be performed in an outpatient setting, often resulting in immediate relief of symptoms.
